Linked Life Data

9339896

Source:http://linkedlifedata.com/resource/pubmed/id/9339896

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
4
pubmed:dateCreated
1997-11-14
pubmed:abstractText
Since the first description of the helper-free retrovirus vector by Mann et al. (1983), many improvements have been introduced to the system to increase titer, or to achieve better expression of the transduced genes in cells of different lineage. The typical form of recombinant retrovirus vector utilizes its 5' long terminal repeat (LTR) as a promoter unit for the transcription of the inserted gene(s), which allows only the constitutive expression of the inserted gene(s) in target cells. Although constitutive expression of the delivered gene(s) in target cells may be sufficient for some purposes, controlled expression of gene(s) in target cells or tissues would be favorable in many basic and clinical applications. To circumvent these problems, we developed a new retroviral vector that allows controlled expression of the inserted genes. With these new retroviral vectors, the expression level of the inserted genes can be controlled up to 200-fold in the presence of a minimum amount of tetracycline. We think these new retroviral vectors will be useful in regulating the expression of the genes delivered in vivo.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Aug
pubmed:issn
1016-8478
pubmed:author
pubmed:issnType
Print
pubmed:day
31
pubmed:volume
7
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
514-20
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed:year
1997
pubmed:articleTitle
Tetracycline-mediated suppression of gene expression with a new dicistronic retroviral vector.
pubmed:affiliation
Laboratory of Tumor Immunology, Korea Cancer Center Hospital, Seoul.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't